

Spinraza® (nusinersen)

When requesting Spinraza® (nusinersen), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-Approved Indication

Spinraza is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.

Coverage Guidelines

Treatment of spinal muscular atrophy (SMA)

An individual must meet **all** of the following criteria for initial authorization:

- Has had a genetic test confirming the diagnosis of SMA with bi-allelic pathogenic variants in the survival motor neuron 1 (SMN1) gene (e.g., homozygous deletion, compound heterozygous mutation, a variety of other rare mutations) *[documentation required]*;
- Has two or three survival motor neuron 2 (SMN2) gene copies OR has four SMN2 gene copies with symptoms consistent with Types 1, 2, or 3 SMA *[documentation required]*;
- Baseline motor ability assessment that suggests SMA (based on age, motor ability, and development) is provided from one of the following exams *[documentation required]*:
 - o Bayley Scales of Infant and Toddler Development;
 - o Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND);
 - o Hammersmith Functional Motor Scale Expanded (HFMSE);
 - o Hammersmith Infant Neurological Exam Part 2 (HINE-2);
 - o Motor Function Measure-32 Items (MFM-32);
 - o Revised Upper Limb Module (RULM) test;
 - o World Health Organization motor milestone scale;
- Has not received Zolgensma in the past;
- For a patient currently receiving or who has received prior treatment with Evrysdi (risdiplam oral solution), further therapy with Evrysdi will be discontinued;
- Spinraza is prescribed by or in consultation with a physician who specializes in the management of spinal muscular atrophy and/or neuromuscular disorders.

An individual must meet all of the following criteria for re-authorization:

- Has had a genetic test confirming the diagnosis of SMA with bi-allelic pathogenic variants in the survival motor neuron 1 (SMN1) gene (e.g., homozygous deletion, compound heterozygous mutation, a variety of other rare mutations);
- Has two or three survival motor neuron 2 (SMN2) gene copies OR has four SMN2 gene copies with symptoms consistent with Types 1, 2, or 3 SMA;
- Has not received Zolgensma in the past;
- For a patient currently receiving or who has received prior treatment with Evrysdi (risdiplam oral solution), further therapy with Evrysdi will be discontinued;
- Spinraza is prescribed by or in consultation with a physician who specializes in the management of spinal muscular atrophy and/or neuromuscular disorders;
- Four months has elapsed since the last dose;
- Must meet one of the following:
 - o Has experienced a positive clinical response (e.g., improvement or stabilization) from pretreatment baseline from one of the following exams *[documentation required]*:
 - Bayley Scales of Infant and Toddler Development;
 - Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND);
 - Hammersmith Functional Motor Scale Expanded (HFMSE);
 - Hammersmith Infant Neurological Exam Part 2 (HINE-2);
 - Motor Function Measure-32 Items (MFM-32);
 - Revised Upper Limb Module (RULM) test;
 - World Health Organization motor milestone scale; OR
 - o Has responded to Spinraza therapy and continues to benefit from ongoing Spinraza therapy by the most recent (within the past 4 months) physician monitoring/assessment tools (e.g., decrease in the frequency of respiratory infections or complications, reduced need for respiratory support, prevention of permanent assisted ventilation, pulmonary function tests showing improvement, and/or bulbar function test results suggest benefits) *[documentation required]*.

Approval duration (initial): 3 months

Approval duration (renewal): 4 months (one dose)

Dosing Recommendation

Spinraza is administered intrathecally.

The recommended dose is 12 mg (5mL) per administration. Initiate Spinraza treatment with 4 loading doses. The first three loading doses should be administered at 14-day intervals. The 4th loading dose should be administered 30 days after the 3rd dose. A maintenance dose should be administered once every 4 months thereafter.

References

1. Spinraza® intrathecal injection [prescribing information]. Cambridge, MA: Biogen; February 2023.
2. Arnold ES, Fischbeck KH. Spinal muscular atrophy. *Handb Clin Neurol*. 2018;148:591-601.
3. Prior TW, Leach ME, Finanger E. Spinal Muscular Atrophy. 2000 Feb 24 [Updated 2020 December 3]. In: Adam MP, Ardinger HH, Pagon RA, et al, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Available at: <https://www.ncbi.nlm.nih.gov/books/NBK1352/>. Accessed on October 30, 2023.
4. Nicolau S, Waldrop MA, Connolly AM, et al. Spinal muscular atrophy. *Semin Pediatr Neurol*. 2021;37:100878.
5. Yeo CJJ, Darras BT. Overturning the paradigm of spinal muscular atrophy as just a motor neuron disease. *Pediatr Neurol*. 2020;109:12-19.
6. Pierzchlewicz K, Kepa I, Podogrodzki J, Kotulska K. Spinal muscular atrophy: the use of functional motor scales in the era of disease-modifying treatment. *Child Neurol Open*. 2021;8:1-9.
7. Evrysdi® oral solution [prescribing information]. South San Francisco, CA: Genentech; February 2024.
8. Zolgensma® intravenous infusion [prescribing information]. Bannockburn, IL: Novartis; October 2023.
9. Finkel RS, Mercuri E, Darras BT, et al, for the ENDEAR Group. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. *N Engl J Med*. 2017;377(18):1723-1732.
10. Mercuri E, Darras BT, Chiriboga JW, et al, for the CHERISH Study Group. Nusinersen versus sham control in later-onset spinal muscular atrophy. *N Engl J Med*. 2018;378:625-635.
11. De Vivo DC, Bertini E, Swoboda KJ, et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: interim efficacy and safety results from the Phase 2 NURTURE study. *Neuromuscul Dis*. 2019;29:842-856.
12. Acsadi G, Crawford TO, Muller-Felber W, et al. Safety and efficacy of nusinersen in spinal muscular atrophy: the EMBRACE study. *Muscle Nerve*. 2021;63:668-677.
13. Wurster CD, Winter B, Bollinsky K, et al. Intrathecal administration of nusinersen in adolescent and adult SMA type 2 and 3 patients. *J Neurol*. 2019;266(1):183-194.
14. Stolte B, Totzeck A, Kizina K, et al. Feasibility and safety of intrathecal treatment with nusinersen in adult patients with spinal muscular atrophy. *Ther Adv Neurol Disord*. 2018;11:1-9.
15. Hagenacker T, Wurster CD, Funther R, et al. Nusinersen in adults with 5q spinal muscular atrophy; a non-interventional, multicenter, observational cohort study. *Lancet Neurol*. 2020;19:317-325.
16. Jochmann E, Steinbach, R, Jochmann T, et al. Experiences from treating seven adult 5q spinal muscular atrophy patients with nusinersen. *Ther Adv Neurol Disord*. 2020;13:1-11.
17. Osmanovic A, Ranxha G, Kumpe M, et al. Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy. *J Neurol*. 2020;267(8):2398-2407.
18. Walter MC, Wenninger S, Thiele S, et al. *J Neuromuscul Dis*. Safety and treatment effects of nusinersen in longstanding adult 5q-SMA Type 3 – a prospective observational study. *J Neuromuscul Dis*. 2019;6(4):453-465.
19. Veerapandian A, Eichinger K, Guntrum D, et al. Nusinersen for older patients with spinal muscular atrophy: a real-world clinical setting experience. *Muscle Nerve*. 2020;61:218-242.
20. Vazquez-Costa JF, Povedano M, Nascimiento-Osorio AE, et al. Nusinersen in adult patients with 5q spinal muscular atrophy: a multicenter observational cohorts' study. *Eur J Neurol*. 2022;29(11):3337-3346.
21. Fainmesser Y, Drory VE, Ben-Shushan S, et al. Long-term follow-up of nusinersen efficacy and safety in adult patients with spinal muscular atrophy types 2 and 3. *Neuromuscul Disord*. 2022;32(6):451-459.
22. Rad N, Cai H, Weiss MD. Management of spinal muscular atrophy in the adult population. *Muscle Nerve*. 2022;65(5):498-507.
23. Duong T, Wolford C, McDermott, et al. Nusinersen treatment in adults with spinal muscular atrophy. *Neurol Clin Pract*. 2021;11(3):e317-e327.
24. Pera MC, Coratti G, Bovis F, et al, for the iSMAC group. Nusinersen in pediatric and adult patients with type III spinal muscular atrophy. *Ann Clin Transl Neurol*. 2021;8(8):1622-1634.
25. Maggi L, Bello L, Bonanno S, et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. *J Neurol Neurosurg Psychiatry*. 2020;91:1166-1174.
26. Konersman CG, Swing E, Yaszay B, et al. Nusinersen treatment of older children and adults with spinal muscular atrophy. *Neuromuscul Disord*. 2021;31:183-193.
27. Glascock J, Sampson J, Haidet-Phillips A, et al. Treatment algorithm for infants diagnosed with spinal muscular atrophy through newborn screening. *J Neuromuscul Dis*. 2018;5:145-158.
28. Glascock J, Sampson J, Connolly AM, et al. Revised recommendations for the treatment of infants diagnosed with spinal muscular atrophy via newborn screening who have 4 copies of SMN2. *J Neuromuscul Dis*. 2020;7(2):97-100.